 |
|
|
| |
ONYX-I: Safety and Efficacy of Ombitasvir/Paritaprevir/Ritonavir and Dasabuvir in Asian Adults With Genotype 1b Chronic Hepatitis C Virus Infection - A Randomized, Double-Blind, Placebo-Controlled Study
|
| |
| |
Reported by Jules Levin
AASLD 2016 Nov 11-15 Boston, MA
Lai Wei1, Jinlin Hou2, Yan Luo3, Jeong Heo4, Chi-Jen Chu5, Zhongping Duan6, Mong Cho7, Jun Cheng8, Jun Li9, Jidong Jia10, Wenjing Lu3, Tami Pilot-Mati as3, Niloufar Mobashery3, Wan-Long Chuang11
1Peking University Peoples Hospital, Beijing, China; 2Nanfang Hospital, Guangzhou, China; 3AbbVie Inc., North Chicago, Illinois, United States; 4Department of Internal Medicine, College of Medicine, Pusan Nati onal University and Medical Research Insti tute, Pusan Nati onal University Hospital, Busan, Republic of Korea;
5Taipei Veterans General Hospital, Taipei City, Taiwan; 6Beijing Youan Hospital Capital Medical University, Beijing, China; 7Pusan Nati onal University Yangsan Hospital, Yangsan, Korea; 8Beijing Di Tan Hospital, Capital Medical University, Beijing, China; 9The First Affi liated Hospital with Nanjing Medical University, Nanjing,
Jiangsu Province, China; 10Beijing Friendship Hospital, Capital Medical University, Beijing, China; 11Kaohsiung Medical University, Kaohsiung City, Taiwan
|
| |
|
|
|
|
|
